Mergers & Acquisitions ·
Armada Acquisition Corp. III agrees to merge with Brains Bioceutical in $750M deal
AACIArmada Acquisition Corp. III
Armada Acquisition Corp. III entered into a definitive business combination agreement with Brains Bioceutical Corp., valuing the target at an implied pre-money equity value of approximately $750.0 million. The transaction involves Armada III merging with Brains, which will continue as Brains Therapeutics Corp. and trade on Nasdaq under the ticker symbol "BAPI". Existing Brains shareholders are expected to roll 100% of their equity into the combined company. The deal is subject to shareholder approvals, regulatory clearances, and other customary closing conditions, with an expected completion in the second quarter of 2027. Armada Acquisition Corp. III is a special purpose acquisition company formed for effecting business combinations. Brains Bioceutical Corp. is a pharmaceutical company specializing in cannabinoid-based therapeutics and API manufacturing.